These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24868521)

  • 1. Hyperammonemia associated with valproic acid concentrations.
    Vázquez M; Fagiolino P; Maldonado C; Olmos I; Ibarra M; Alvariza S; Guevara N; Magallanes L; Olano I
    Biomed Res Int; 2014; 2014():217269. PubMed ID: 24868521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation.
    Schiavo A; Maldonado C; Vázquez M; Fagiolino P; Trocóniz IF; Ibarra M
    Eur J Pharm Sci; 2023 Apr; 183():106399. PubMed ID: 36740101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carnitine in the treatment of valproic acid-induced toxicity.
    Lheureux PE; Hantson P
    Clin Toxicol (Phila); 2009 Feb; 47(2):101-11. PubMed ID: 19280426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder.
    Yokoyama S; Yasui-Furukori N; Nakagami T; Miyazaki K; Ishioka M; Tarakita N; Kubo K; Sugawara N; Shimoda K
    Ther Drug Monit; 2020 Oct; 42(5):766-770. PubMed ID: 32482992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
    Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
    Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report.
    Maldonado C; Guevara N; Silveira A; Fagiolino P; Vázquez M
    J Int Med Res; 2017 Jun; 45(3):1268-1272. PubMed ID: 28425821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs.
    Verrotti A; Greco R; Morgese G; Chiarelli F
    Int J Clin Lab Res; 1999; 29(1):36-40. PubMed ID: 10356662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levocarnitine for the Treatment of Valproic Acid-Induced Hyperammonemic Encephalopathy in Children: The Experience of a Large, Tertiary Care Pediatric Hospital and a Poison Center.
    Glatstein M; Bonifacio Rino P; de Pinho S; Scolnik D; Pivko-Levi D; Hoyte C
    Am J Ther; 2019; 26(3):e344-e349. PubMed ID: 29232283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
    Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
    Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential ammonia decay kinetics indicates more than one concurrent etiological mechanism for symptomatic hyperammonemia caused by valproate overdose.
    Mojumder DK; De Oleo RR
    Indian J Pharmacol; 2014; 46(3):345-7. PubMed ID: 24987188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy.
    Itoh H; Suzuki Y; Fujisaki K; Sato Y; Takeyama M
    Biol Pharm Bull; 2012; 35(6):971-4. PubMed ID: 22687541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report.
    Cattaneo CI; Ressico F; Valsesia R; D'Innella P; Ballabio M; Fornaro M
    Medicine (Baltimore); 2017 Sep; 96(39):e8117. PubMed ID: 28953637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions.
    Duman B; Can KC; Ağtaş-Ertan E; Erdoğan S; İlhan RS; Doğan Ö; Kumbasar H; Çamsarı UM
    Gen Hosp Psychiatry; 2019; 59():67-72. PubMed ID: 31276904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
    Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carnitine deficiency and hyperammonemia associated with valproic acid therapy.
    Ohtani Y; Endo F; Matsuda I
    J Pediatr; 1982 Nov; 101(5):782-5. PubMed ID: 6813444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of L-carnitine supplementation on acute valproate intoxication.
    Murakami K; Sugimoto T; Woo M; Nishida N; Muro H
    Epilepsia; 1996 Jul; 37(7):687-9. PubMed ID: 8681902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperammonemia following intravenous valproate loading.
    DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
    Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
    Kwack DW; Kim DW
    Clin Neurol Neurosurg; 2023 Oct; 233():107962. PubMed ID: 37717359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of carnitine supplementation during valproic acid therapy.
    Raskind JY; El-Chaar GM
    Ann Pharmacother; 2000 May; 34(5):630-8. PubMed ID: 10852092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.